Phase II study of imatinib in advanced chordoma.

Détails

ID Serval
serval:BIB_B455B25BFCF8
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Phase II study of imatinib in advanced chordoma.
Périodique
Journal of Clinical Oncology
Auteur(s)
Stacchiotti S., Longhi A., Ferraresi V., Grignani G., Comandone A., Stupp R., Bertuzzi A., Tamborini E., Pilotti S., Messina A., Spreafico C., Gronchi A., Amore P., Vinaccia V., Casali P.G.
ISSN
1527-7755 (Electronic)
ISSN-L
0732-183X
Statut éditorial
Publié
Date de publication
2012
Volume
30
Numéro
9
Pages
914-920
Langue
anglais
Notes
Publication types: Journal Article
Résumé
PURPOSE: To explore the antitumor activity of imatinib in patients with advanced platelet-derived growth factor β (PDGFB)/PDGF receptor β (PDGFRB)-positive chordomas.¦PATIENTS AND METHODS: In a collaborative Italian-Swiss, prospective, phase II clinical study conducted from November 2004 through April 2006, 56 patients with advanced PDGFB and/or PDGFRB chordoma received 800 mg/d of imatinib until progression. The primary end point was the overall tumor response rate (ORR), defined by RECIST. Secondary, exploratory end points included tissue response (ie, changes in tumor density or signal intensity/contrast enhancement, and/or [18F]-fluorodeoxyglucose positron emission tomography [PET] uptake), overall survival, progression-free survival (PFS), and pain score.¦RESULTS: Among 50 patients evaluable by RECIST, the best response was one partial response (PR) obtained at 6 months (ORR, 2%). There were 35 patients with stable disease (SD, 70%) and a 64% clinical benefit rate (ie, RECIST complete response + PR + SD ≥ 6 months). A minor dimensional response (< 20%) was detected in nine patients. A maximum standard uptake value decrease ≥ 25% was observed in 10 (39%) of 26 patients evaluable for PET response at 3 months. Changes in the Brief Pain Inventory score were consistent with the response assessment. Median PFS (intention-to-treat population, 56 patients) was 9 months. No unexpected toxicities were observed.¦CONCLUSION: This is the largest phase II study in chordoma to date. It confirms anecdotal evidence that imatinib has antitumor activity in this orphan disease, and therefore, it is worth further investigation.
Pubmed
Web of science
Création de la notice
05/05/2012 15:52
Dernière modification de la notice
20/08/2019 15:22
Données d'usage